Pancragen

Pancragen is a synthetic tetrapeptide, Lys-Glu-Asp-Trp, studied for pancreatic endocrine and metabolic endpoints. The evidence base is stronger than many related bioregulators but still not strong enough for clinical treatment claims. Primary sources include small studies in old female rhesus monkeys, a cell-culture study of pancreatic differentiation markers, and a small human study in older adults with type 2 diabetes. In rhesus monkeys, Pancragen was reported to improve glucose disappearance rate and normalize insulin and C-peptide dynamics after glucose administration. In human older adults with type 2 diabetes, Pancragen was associated with improved fasting and glucose-tolerance-test measures, but the study was small.

Pancreatic Endocrine Models

In old rhesus monkeys, Pancragen was associated with improved glucose disappearance and insulin/C-peptide dynamics after glucose administration ^[1][2].

Pancreatic Cell Differentiation

In pancreatic cell cultures, Pancragen stimulated expression of acinar and islet differentiation factors including Pdx1, Ptf1a, Pax6, Pax4, Foxa2, and NKx2.2 ^[3].

Small Human Metabolic Study

A small study of older adults with type 2 diabetes reported lower fasting and glucose-challenge measures, but this does not establish diabetes treatment efficacy ^[4].

Limited Human Data

Pancragen has limited human data and small animal studies; it is not supported by large randomized trials or modern regulatory labeling for diabetes or pancreatic disease ^[1][2][4].

Treatment Claim Limits

Pancragen should not be described as a treatment for diabetes, impaired glucose tolerance, pancreatitis, pancreatic insufficiency, or metabolic disease ^[1][2][3][4].